超分割再程放疗对复发或第二原发头颈癌患者生活质量的影响:一项前瞻性单机构研究
这项前瞻性观察研究纳入58例适合超分割再程放疗的复发或第二原发头颈癌患者,给予每次1.5 Gy、每日两次、每周五天、共三周(姑息)或四周(根治/局部控制)、总剂量45/60 Gy的方案。多数患者在再程放疗后3个月和12个月报告健康相关生活质量维持,尽管许多患者观察到严重毒性;有限比例患者可获得长期生存。
要点
- 58例患者中60%在3个月、56%在12个月报告总体生活质量维持或改善。
- 根治、局部控制和姑息意向患者的中位生存分别为23、10和14个月。
- 存活患者中12个月和36个月无病比例分别为58%和48%。
核心结论
- 多数头颈癌患者在超分割再程放疗后3个月和12个月报告健康相关生活质量维持,尽管许多患者观察到严重毒性。
- 有限比例患者可获得长期生存。
研究设计与样本
- 前瞻性观察研究,纳入58例复发或第二原发头颈癌患者(37例复发、21例第二原发),年龄≥18岁,计划接受再程放疗且能回答问卷。
- 放疗方案为每次1.5 Gy、每日两次、每周五天,姑息组三周、根治/局部控制组四周,总剂量45/60 Gy。
- 毒性采用CTCAE v3在基线、治疗结束及3、6、12、36个月随访时评分;健康相关生活质量采用EORTC QLQ-C30和EORTC QLQ-H&N35在治疗前及至36个月共八次测量;生存分析采用Kaplan-Meier法。
主要发现
- 除2例患者外,其余患者均按计划完成治疗。
- ≥3级毒性从治疗前至治疗结束时增加,随访期间改善。
- 总体生活质量和头颈疼痛平均评分从治疗前至3个月保持稳定。
- 根治、局部控制和姑息意向患者的中位生存(范围)分别为23(2-53)、10(1-66)和14(3-41)个月。
- 存活患者中12个月和36个月无病比例分别为58%和48%。
关键数值与推荐
- 主要结局中,总体生活质量和头颈疼痛变化评分≥10分视为临床显著,双侧P值<0.05视为统计学显著。
- 60%患者在3个月、56%患者在12个月报告总体生活质量维持或改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Describe the clinical outcome of hyperfractionated re-irradiation (HFRT) in patients with recurrent or second primary (SP) head and neck cancer (HNC). METHODS: This prospective observational study included HNC patients eligible for HFRT. Inclusion criteria: age ≥18 years, recurrent or SP HNC, planned re-irradiation and ability to respond to questionnaires. Patients received 1.5 Gy twice daily, five days a week for three (palliative) or four (curative/local control) weeks, total dose 45/60 Gy. Toxicity was scored with CTCAE v3 at baseline, end of treatment, at three, six, 12 and 36 months follow-up. Health-related quality of life (HRQoL) was measured with EORTC QLQ-C30 and EORTC QLQ-H&N35, pre-treatment and eight times until 36 months. In the main outcome (Global quality of life and H&N Pain), a change score of ≥10 was considered clinically significant, and p-values < 0.05 (two-sided) statistically significant. The Kaplan-Meier method was used for survival analyses. RESULTS: Over four years from 2015, 58 patients were enrolled (37 recurrent and 21 SP). All, but two patients completed treatment as planned. Toxicity (≥grade 3) increased from pre-treatment to end of treatment with improvement in the follow-up period. The mean Global quality of life (QoL) and H&N Pain scores were stable from pre-treatment to three months. Maintained/ improved Global QoL was reported by 60% of patients at three months and 56% of patients at 12 months. For patients with curative, local control and palliative intent, the median survival (range) was 23 (2-53), 10 (1-66) and 14 (3-41) months respectively. Of those alive, the proportion of disease-free patients at 12 and 36 months, were 58% and 48%, respectively. CONCLUSION: Most HNC patients reported maintained HRQoL at three and 12 months after HFRT despite serious toxicity observed in many patients. Long-term survival can be achieved in a limited proportion of the patients.
引用
- Amdal CD, Moan JM, Dale E, et al. Impact of hyperfractionated re-irradiation on quality of life in patients with recurrent or second primary head and neck cancer, a prospective single institutional study. Clin Transl Radiat Oncol. 2023. PMID: 37415638. doi:10.1016/j.ctro.2023.100654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。